Table 3.
Patient Demographics and Clinical Characteristics Pre- and Post-Matching of Covariates for CGRP mAb and SOC 12-Month Follow-Up Cohort
| Demographics and Clinical Characteristics | Pre-Matching | Post-Matching | ||||
|---|---|---|---|---|---|---|
| CGRP mAb (N=4528) | SOC (N=10,897) | Std Diff | CGRP mAb (N=3082) | SOC (N=3082) | Std Diff | |
| Age (years), mean (SD) | 45.1 (11.3) | 41.3 (12.3) | 0.323 | 44.4 (11.3) | 44.2 (12.0) | 0.018 |
| Female, n (%) | 3904 (86.2) | 9275 (85.1) | 0.032 | 2641 (85.7) | 2676 (86.8) | 0.033 |
| Region, n (%) | ||||||
| Northeast | 1071 (23.7) | 1726 (15.8) | 0.197 | 679 (22.0) | 500 (16.2) | 0.148 |
| North central | 930 (20.5) | 2476 (22.7) | 0.053 | 617 (20.0) | 713 (23.1) | 0.076 |
| South | 1899 (41.9) | 5246 (48.1) | 0.125 | 1354 (43.9) | 1424 (46.2) | 0.046 |
| West | 617 (13.6) | 1427 (13.1) | 0.016 | 427 (13.9) | 435 (14.1) | 0.007 |
| Unknown | 11 (0.2) | 22 (0.2) | 0.009 | 5 (0.2) | 10 (0.3) | 0.033 |
| Insurance plan type, n (%) | ||||||
| Comprehensive/ indemnity | 153 (3.4) | 415 (3.8) | 0.023 | 105 (3.4) | 101 (3.3) | 0.007 |
| EPO/PPO | 2604 (57.5) | 5653 (51.9) | 0.113 | 1734 (56.3) | 1730 (56.1) | 0.003 |
| POS/POS with capitation | 273 (6.0) | 712 (6.5) | 0.021 | 198 (6.4) | 169 (5.5) | 0.040 |
| HMO | 500 (11.0) | 1480 (13.6) | 0.077 | 339 (11.0) | 345 (11.2) | 0.006 |
| CDHP/HDHP | 960 (21.2) | 2495 (22.9) | 0.041 | 674 (21.9) | 694 (22.5) | 0.016 |
| Other/unknown | 38 (0.8) | 142 (1.3) | 0.045 | 32 (1.0) | 43 (1.4) | 0.033 |
| Provider, n (%) | ||||||
| Neurology | 1414 (31.2) | 2827 (25.9) | 0.117 | 944 (30.6) | 993 (32.2) | 0.034 |
| Primary carea | 1022 (22.6) | 4578 (42.0) | 0.425 | 800 (26.0) | 771 (25.0) | 0.022 |
| Acute hospital care, ER | 310 (6.8) | 549 (5.0) | 0.077 | 186 (6.0) | 188 (6.1) | 0.003 |
| Radiology, laboratory, pathology | 201 (4.4) | 283 (2.6) | 0.100 | 132 (4.3) | 90 (2.9) | 0.073 |
| Other/unknown | 1581 (34.9) | 2660 (24.4) | 0.232 | 1020 (33.1) | 1040 (33.7) | 0.014 |
| DCI, mean (SD) | 0.4 (0.9) | 0.4 (0.9) | 0.029 | 0.5 (0.9) | 0.4 (0.9) | 0.012 |
| Chronic clinical conditions, n (%) | ||||||
| Anxiety | 1483 (32.8) | 3496 (32.1) | 0.014 | 1011 (32.8) | 1023 (33.2) | 0.008 |
| Asthma | 594 (13.1) | 1227 (11.3) | 0.057 | 424 (13.8) | 330 (10.7) | 0.093 |
| Chronic migraine | 3125 (69.0) | 2355 (21.6) | 1.083 | 1749 (56.7) | 1690 (54.8) | 0.039 |
| Depression | 1249 (27.6) | 2573 (23.6) | 0.091 | 820 (26.6) | 828 (26.9) | 0.006 |
| Hypertension | 1140 (25.2) | 2729 (25.0) | 0.003 | 798 (25.9) | 810 (26.3) | 0.009 |
| Nausea | 816 (18.0) | 1993 (18.3) | 0.007 | 564 (18.3) | 563 (18.3) | 0.001 |
| Obesity | 650 (14.4) | 1772 (16.3) | 0.053 | 454 (14.7) | 519 (16.8) | 0.058 |
| Osteoarthritis | 517 (11.4) | 909 (8.3) | 0.103 | 317 (10.3) | 331 (10.7) | 0.015 |
| Sleep disorder | 1272 (28.1) | 2214 (20.3) | 0.182 | 841 (27.3) | 778 (25.2) | 0.046 |
Notes: Covariates with Std Diff ≥0.1 are bolded, suggesting potential imbalance between cohorts. The 1:1 propensity score matched CGRP mAb and SOC cohorts were well-balanced. aIncludes family practice, internal medicine, obstetrics/gynecology, and nurse practitioner.
Abbreviations: CDHP, consumer-driven health plan; CGRP mAb, calcitonin gene-related peptide ligand or receptor-targeted monoclonal antibody; DCI, Deyo-Charlson comorbidity index; EPO, exclusive provider organization; ER, emergency room; GMB, galcanezumab; HDHP, high deductible health plan; HMO, health maintenance organization; N, number of patients in the cohort; n, number of patients in each category; POS, point of service; PPO, preferred provider organization; SD, standard deviation; SOC, standard-of-care; Std Diff, standardized difference.